Any current/future capex/capital investment/strategic investment?

Planned CAPEX of around ₹100 crores in 2026 to expand tablet capacity at the old Goa plant from 700-800 million to 1.2-1.3 billion tablets per month, also tripling soft gel capacity. Expansion focused on acquiring adjacent land and constructing new blocks with shared infrastructure to achieve operating leverage. Investment targeted to handle revenue growth beyond ₹4,000 crores and enable scaling towards ₹5,000 crores in the longer term. Organic expansion in Europe, especially Germany, with operations starting in FY'26 including hiring employees and infrastructure setup. Active pursuit of small

Future growth expectations in sales/revenue/volumes?

The US business is expected to remain a major growth driver, with potential to double revenue in 4-5 years, aiming for around $300 million in 3 years, though geopolitical risks cause some caution. The US market opportunity for private label OTC is several billion dollars; Marksans is among the top four players but far behind the market leaders. Europe, especially Germany and four other key countries, is targeted for organic growth starting in 2026, with operations expected to scale in the second half of 2026. UK market expected to double revenue within 5-7 years with new product launches

Future growth expectations in earnings/operating earnings/profits/EPS?

EBITDA margin expected to settle around 19% to 20% range in FY'26, with potential to be slightly better; north of 20% possible but 19%-20% is a safe assumption. Operating leverage will improve as revenue grows, but initial investments in new markets and infrastructure may increase costs temporarily. Revenue target to reach Rs. 3,000 crores by FY'27 and Rs. 5,000 crores by FY'30, indicating steady long-term growth. EPS for H1 FY'26 at Rs. 3.5, with quarterly EPS of Rs. 2.2 in Q2 FY'26, showing growth alongside revenues. Growth drivers include strong product pipelines in the U.S., U.K., and Euro

Current/ Expected Orderbook/ Pending Orders?

Current U.S. order book stands between $225 to $230 million, indicating a strong position. (Page 4) The company has ample manufacturing capacity, especially at the Teva plant, currently under 30% utilized, allowing for expansion without immediate capacity constraints. (Page 7) Despite tariff uncertainties over the last six months, clarity has recently emerged, improving client confidence and order momentum. (Pages 7, 10) The company is targeting an order book of $300 million within three years as part of its growth outlook. (Page 8) Growth in other geographies such as Europe and Canada is also

Any current/future new fundraising through debt or equity?

The document does not mention any current or planned fundraising through debt or equity. It states the company continues to remain debt-free, with a cash balance of Rs. 666.5 crore as of September 30, 2025. There is a focus on internal cash flows and budgets for CAPEX, such as a planned CAPEX of about Rs. 100 crores in 2026 for capacity expansion. No specific plans for raising funds via equity or debt are discussed. Future investments, including expansions and acquisitions, appear to be funded through cash on hand and internal accruals.

IN US

Sale is live|00:00:00left today

Marksans Pharma LtdQ3 FY25Pharmaceuticals & Biotechnology

Marksans Pharma Ltd Q3 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹265P/E: 23.2Market Cap: ₹8.4K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 2

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2

→The US business is expected to remain a major growth driver, with potential to double revenue in 4-5 years, aiming for around $300 million in 3 years, though geopolitical risks cause some caution.
→The US market opportunity for private label OTC is several billion dollars; Marksans is among the top four players but far behind the market leaders.
→Europe, especially Germany and four other key countries, is targeted for organic growth starting in 2026, with operations expected to scale in the second half of 2026.
→UK market expected to double revenue within 5-7 years with new product launches and improving pricing environment.
→CAPEX planned in 2026 (~Rs. 100 crores) to increase tablet capacity from 700-800 million to 1.2-1.3 billion tablets per month and triple soft gel capacity, enabling revenue growth beyond Rs. 4,000 crores.
→Longer-term revenue target is Rs. 5,000 crores by FY 2030.
→Overall growth rate historically ~20% plus; sustainable EBITDA margins targeted in 19-20%+ range as revenue scales.

Margin guidance

Category 2

→EBITDA margin expected to settle around 19% to 20% range in FY'26, with potential to be slightly better; north of 20% possible but 19%-20% is a safe assumption.
→Operating leverage will improve as revenue grows, but initial investments in new markets and infrastructure may increase costs temporarily.
→Revenue target to reach Rs. 3,000 crores by FY'27 and Rs. 5,000 crores by FY'30, indicating steady long-term growth.
→EPS for H1 FY'26 at Rs. 3.5, with quarterly EPS of Rs. 2.2 in Q2 FY'26, showing growth alongside revenues.
→Growth drivers include strong product pipelines in the U.S., U.K., and Europe, with expectations of improved margins through cost efficiencies and operating leverage.
→Infrastructure expansion planned to support growth beyond Rs. 4,000 crores, including CAPEX of ~Rs. 100 crores in 2026 for capacity enhancement.
→Overall, sustainable EBITDA margin improvement and revenue growth expected, supported by strategic investments and market expansion.

3 more insights locked — sign up free to unlock

Fundraise plans

→The document does not mention any current or planned fundraising through debt or equity.
→It states the company continues to remain debt-free, with a cash balance of Rs. 666.5 crore as of September 30, 2025.
→There is a focus on internal cash flows and budgets for CAPEX, such as a planned CAPEX of about Rs. 100 crores in 2026 for capacity expansion.
→No specific plans for raising funds via equity or debt are discussed.
→Future investments, including expansions and acquisitions, appear to be funded through cash on hand and internal accruals.

Order book

Yes

→Current U.S. order book stands between $225 to $230 million, indicating a strong position. (Page 4)
→The company has ample manufacturing capacity, especially at the Teva plant, currently under 30% utilized, allowing for expansion without immediate capacity constraints. (Page 7)
→Despite tariff uncertainties over the last six months, clarity has recently emerged, improving client confidence and order momentum. (Pages 7, 10)
→The company is targeting an order book of $300 million within three years as part of its growth outlook. (Page 8)
→Growth in other geographies such as Europe and Canada is also expected to contribute to the order pipeline in coming years. (Pages 6, 12)

Capex plans

Yes

→Planned CAPEX of around ₹100 crores in 2026 to expand tablet capacity at the old Goa plant from 700-800 million to 1.2-1.3 billion tablets per month, also tripling soft gel capacity.
→Expansion focused on acquiring adjacent land and constructing new blocks with shared infrastructure to achieve operating leverage.
→Investment targeted to handle revenue growth beyond ₹4,000 crores and enable scaling towards ₹5,000 crores in the longer term.
→Organic expansion in Europe, especially Germany, with operations starting in FY'26 including hiring employees and infrastructure setup.
→Active pursuit of smaller M&A opportunities across Europe planned for 2026 to complement organic growth.
→Investing in new geographies such as Canada and four European countries, balancing both organic and inorganic growth strategies.
→No current plans to expand manufacturing capacity in the US; focus remains on leveraging low-cost Indian manufacturing base.

How does Marksans Pharma Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Marksans Pharma Ltd

Rev 2Mar 2

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Marksans Pharma Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio